DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07430332

Not yet recruitingPhase 2

GLP-1 RA for Stage 1 Type 1 Diabetes

Leveraging Semaglutide for Preservation of Beta Cell Function and Restoration of Alpha Cell Function

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

15

estimated

Study population

Type 1 diabetes

Key I/E criterion

—

Primary endpoint

•C-peptide AUC

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07430332
Org study ID2026-0116

Timeline

Milestones

Study first posted2026-02-24actual
Last update posted2026-02-24actual
Study start2027-09-01estimated
Primary completion2029-06-01estimated
Study completion2030-01-01estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Type 1 diabetes

Eligibility

Who can enroll

Minimum age12 Years
Maximum age70 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Stage 1 Type 1 Diabetes
•Screening OGTT with impaired or loss of first phase insulin secretion but no dysglycemia to suggest stage 2 or stage 3 type 1 diabetes

Exclusion criteria

•History of anaphylaxis or allergies to GLP-1 receptor agonists
•Already on a GLP-1 receptor agonist
•History of bariatric surgery
•Personal or family history of cancer such as medullary thyroid cancer
•Personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis
•Severe hypoglycemia within 3 months of study enrollment
•Pregnant, breastfeeding, or the intention of becoming pregnant or not using adequate contraceptive measures
•Adult individuals with BMI < 18.5 kg/m2 and pediatric participants with BMI < 5th percentile

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
3
Other (unclassified)
1

Glycemic / diabetes

3 endpoints
Primary/protocol endpoint

C-peptide area under the curve

Time frame:12 months

C-peptide AUC

change from baseline, improvement

Primary/protocol endpoint

C-peptide area under the curve (AUC)

Time frame:12 months

C-peptide AUC

change from baseline, improvement

Secondary/protocol endpoint

Glucagon secretion

Time frame:12 months

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Stimulated incretin levels

Time frame:12 months

descriptive

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.